U.S. COVID-19 Vaccine Product Information

FDA approved and authorized 2024–2025 Moderna and Pfizer-BioNTech COVID-19 vaccines on August 22, 2024. FDA also authorized 2024–2025 Novavax COVID-19 Vaccine on August 30, 2024. CDC is now updating the product information materials below for these vaccines. See Use of COVID-19 Vaccines in the United States for more information, including recommendations for use of these vaccines in people ages 6 months and older.

Materials for 2024–2025 approved and authorized vaccines coming soon

Pfizer-BioNTech

• At-a-Glance
• Standing Orders:
  • 6 months–4 years of age
  • 5 years of age and older

  Moderna

  • At-a-Glance
  • Standing Orders:
    • 6 months–4 years of age
    • 5 years of age and older

    Novavax

    • At-a-Glance
    • Standing Orders
    • Labels and BUD Guidance
    Education for Patients and Parents

    Immunization providers should provide a Vaccine Information Statement (VIS) or Emergency Use Authorization (EUA) Factsheet for Recipients to a patient, parent, or legal representative before each dose of COVID-19 vaccine.

    • COVID-19 Pfizer-BioNTech Vaccine EUA Fact Sheet for individuals 6 months through 11 years of age
    • COVID-19 Moderna Vaccine EUA Fact Sheet for individuals 6 months through 11 years of age
    • COVID-19 Novavax EUA Recipient-Caregiver Fact Sheet 12 years of age and older
    • COVID-19 Vaccine Information Statement for people 12 years of age and older